


to be due with this amendment; any fees due for added dependent claims 32-34 are offset by cancellation of the twenty-two pending claims 1-3, 5-15, and 24-31, for which fees have already been paid.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned **"Version with markings to show changes made"**.

Applicants note that claims 4 and 16, as amended, and new claims 32 and 33 fall within the invention of Group I as defined by the Restriction Requirement mailed October 1, 2002, Paper No. 8, in this application. As Applicants elected Group I for prosecution in the Response to Restriction Requirement filed December 2, 2002, claims 4, 16, 32 and 33 will presumably be examined after entry of this amendment. Claims 17-23 fall within the invention of Group II as defined by the restriction requirement, and it is believed that new claim 34 should also fall in Group II; thus, these claims will be subject to restriction from the current application.

As claims 17-23 and 34 depend directly or indirectly from claim 4, Applicants respectfully request, should claims 4, 16, 32, and 33 be found allowable, that the method claims 17-23 and 34 be rejoined with claims 4, 16, 32 and 33 as permitted by MPEP 821.04.

The Examiner also requested election of a single disclosed species. In a telephone conference on May 28, 2002, the undersigned agent requested clarification of this requirement, and the Examiner indicated that a single unique chemical compound should be designated. Applicants thus elect the following compound (designated SL-11144):



which is the first compound appearing in claim 4, and the only compound in claim 33. Applicants request rejoinder of the remaining species under 37 C.F.R. § 1.141(a) upon allowance of a claim generic to all species.

In the event that the Patent Office determines that an extension, excess claim fees, and/or other relief is required, Applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 376462000400. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: December 16, 2002

By:



Robert K. Cerpa
Registration No. 39,933

Morrison & Foerster LLP
555 West Fifth Street
Suite 3500
Los Angeles, California 90013-1024
Telephone: (213) 892-5615
Facsimile: (213) 892-5454


VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

4. (Once amended) A conformationally restricted polyamine analog [according to claim 3,] selected from the group consisting of:



and




and any salt or stereoisomer thereof.

16. (Once amended) The polyamine analog of claim [1] 4, further comprising a pharmaceutically acceptable excipient.

17. (Once amended) A method of treating an indication in an individual comprising the step of administering to the individual a therapeutic amount of a polyamine analog of claim [1] 4.


22. (Once amended) A method of suppressing cell growth in an individual comprising the step of administering to the individual a therapeutic amount of a polyamine analog of claim [1] 4.

32. (NEW) A conformationally restricted polyamine analog according to claim 4 of the formula:



and any salt thereof.

33. (NEW) A conformationally restricted polyamine analog according to claim 4 of the formula:



and any salt thereof.

34. (NEW) The method of claim 17, wherein the indication is breast cancer.